Related Experiment Video
Updated: Jun 30, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Protected complex high-risk indicated percutaneous coronary intervention in severe left ventricular dysfunction: an
Saad M Ezad1,2, Mohammad Alkhalil3,4, María Monteagudo-Vela5
1British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK.
Insights
Ischaemic left ventricular dysfunction (ILVD) poses challenges for older patients undergoing complex high-risk indicated percutaneous coronary intervention (CHIP). Temporary mechanical circulatory support, like Impella™, may mitigate risks and improve outcomes in these high-risk patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Heart Failure Research
Background:
- Ischaemic left ventricular dysfunction (ILVD) is a primary cause of heart failure.
- Older patients with ILVD often have complex coronary anatomy, complicating revascularization.
- Traditional revascularization methods like coronary artery bypass grafting offer limited early benefits for older, frail individuals.
Purpose of the Study:
- To explore the role of temporary mechanical circulatory support in complex high-risk indicated percutaneous coronary intervention (CHIP) for patients with ILVD.
- To illustrate a structured approach to Impella-supported CHIP in a challenging patient profile.
- To highlight strategies for mitigating procedural risks in high-risk CHIP patients.
Main Methods:
- Review of registry data on CHIP patients with ILVD and multiple risk factors.
- Discussion of temporary mechanical circulatory support devices, including intra-aortic balloon pumps and microaxial flow pumps (Impella™).
- Case illustration of Impella-supported CHIP in an elderly patient with severe ILVD and complex coronary disease.
Main Results:
- Registry data indicate heightened risk in CHIP patients with multiple adverse features (e.g., low ejection fraction, left main disease, calcification).
- Intra-aortic balloon pump shows no early benefit but suggests improved long-term survival.
- Microaxial flow pumps (Impella™) may provide robust support and reduce late adverse events.
Conclusions:
- Temporary mechanical circulatory support is a viable strategy to manage haemodynamic instability during CHIP procedures in ILVD patients.
- Careful Heart Team evaluation and procedural planning are crucial for optimizing outcomes in Impella-supported CHIP.
- Further data from ongoing randomized trials are anticipated to clarify the role of Impella in CHIP.
Abstract:
Ischaemic left ventricular dysfunction (ILVD) is the leading cause of heart failure and is commonly encountered in cardiac catheterization laboratories. Patients presenting with ILVD are typically older and often have complex coronary anatomy, making revascularization challenging. Although coronary artery bypass grafting improves long-term survival in patients with ILVD compared with medical therapy, the benefit emerges only after a decade and appears limited to younger patients, leaving many older, frail, or comorbid individuals at untenable risk. Such patients are frequently considered for complex high-risk indicated percutaneous coronary intervention (CHIP), where the primary determinant of procedural risk is intra-procedural haemodynamic instability due to limited ventricular reserve and anticipated prolonged ischaemia. Registry data underscore the heightened risk in patients with multiple CHIP features, including ejection fraction ≤30%, left main or multivessel percutaneous coronary intervention, and extensive calcification. Here, temporary mechanical circulatory support has emerged as a strategy to mitigate haemodynamic compromise during CHIP procedures. Although trial data have demonstrated no early benefit with the intra-aortic balloon pump, long-term follow-up suggests improved survival. Alternatively, microaxial flow pumps, such as Impella™, can offer robust haemodynamic support and a reduction in late major adverse events. Although results from the ongoing randomized clinical trials with Impella are pending, careful Heart Team evaluation and procedural planning remain essential to ensure the best possible patient outcomes. Here, we illustrate a structured approach to Impella-supported CHIP in an elderly patient with the presence of ILVD, severely impaired ventricular reserve, and heavily calcified multivessel disease.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization III: Left Heart Catheterization
Cardiomyopathy V: Interprofessional Care
Cardiac Catheterization IV: Nursing Management
Cardiac Catheterization II: Right Heart Catheterization
Cardiomyopathy III: Hypertrophic Cardiomyopathy